-

Twist Bioscience to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences:

  • Cowen 43rd Annual Healthcare Conference in Boston, MA;
    • Fireside chat on Tuesday, March 7 at 1:30 p.m. Eastern Time.
    • SynBio & AI Driven Drug Discovery Panel: Monday, March 6 at 4:40 p.m. Eastern Time.
    • Synthetic Biology Enabling Tools Panel: Tuesday, March 7 at 4:40 p.m. Eastern Time.
  • Barclays Global Healthcare Conference on Tuesday, March 14 in Miami, FL; fireside chat at 2:05 p.m. Eastern Time.

The Cowen fireside chat and panels and Barclays fireside chat will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the fireside chats will be archived for a period of 30 days following the conclusion of the live events.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Contacts

For Twist Bioscience
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
media@twistbioscience.com

Twist Bioscience Corporation

NASDAQ:TWST

Release Versions

Contacts

For Twist Bioscience
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
media@twistbioscience.com

More News From Twist Bioscience Corporation

Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innovation by enabling participating compan...

Twist Bioscience to Present at Baird 2026 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026 at 1:25 pm Eastern Time in New York City. The fireside chat will be webcast live and can be accessed by visiting the “In...

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Twist. The gross proceeds to Twist from the offering, before deducting the underwriting discounts and commissio...
Back to Newsroom